Response to a letter by Jolobe: ARISTOPHANES subgroup analysis of frail and older patients with NVAF receiving low doses of novel oral anticoagulants

2021 ◽  
Author(s):  
G. Y. H. Lip ◽  
S. B. Deitelzweig
Keyword(s):  
Subgroup Analysis ◽  
Older Patients ◽  
Oral Anticoagulants ◽  
Novel Oral Anticoagulants ◽  
Low Doses

Novel Oral Anticoagulants (NOACs) Roundtable – Hot Topics And Current Issues

2015 ◽  
Vol 4 (1) ◽  
pp. 1
Author(s):  
Katrina Mountfort
Keyword(s):  
Oral Anticoagulants ◽  
Novel Oral Anticoagulants

Novel Oral Anticoagulants in Peripheral Artery Disease: Current Evidence

2019 ◽  
Vol 24 (38) ◽  
pp. 4511-4515 ◽  
Author(s):  
A. Koutsoumpelis ◽  
C. Argyriou ◽  
K.M. Tasopoulou ◽  
E.I. Georgakarakos ◽  
G.S. Georgiadis
Keyword(s):  
Peripheral Artery Disease ◽  
Oral Anticoagulants ◽  
Novel Oral Anticoagulants ◽  
Current Evidence ◽  
Peripheral Artery ◽  
Cardiac Events ◽  
Traditional Therapy ◽  
Cardiovascular Morbidity And Mortality ◽  
Increased Risk ◽  
Artery Disease

Background: Peripheral artery disease is a common manifestation of systemic atherosclerosis which strongly correlates to cardiovascular morbidity and mortality. In addition, the progression of peripheral artery disease leads to an increased risk of limb loss. In order to reduce these events, the benchmark of treatment and research over the last years has been the antiplatelet therapy which aims at inhibition of platelet aggregation. Over the last years, new studies combining antiplatelet agents in different therapeutic schemes have been proven efficacious. Unfortunately, patients remain still at high risk of CV events. Novel Oral Anticoagulants have been introduced as alternatives to warfarin, in the prevention and treatment of venous thromboembolism. The rationale of using medication which acts on platelet activation and the coagulation pathway of thrombosis has led investigators to examine the role of Noac's in preventing CV events in patients with peripheral artery disease, stable or unstable. Methods: The aim of this study is to review the current evidence with respect to recently published studies concerning the use of Novel anticoagulants in peripheral artery disease. Results: The Compass trial has shown that a combination of rivaroxaban with traditional therapy may produce promising results in reducing amputation rates, stroke, cardiac events, and mortality, however, there are still safety issues with bleeding requiring acute care. The ePAD study has provided us with insight concerning safety and efficacy after peripheral angioplasty or stenting and actually the need for further research. The Voyager Pad study, following the steps of Compass, is studying the effect and safety of the addition of rivaroxaban to traditional therapy in the highest risk population aka patients undergoing peripheral revascularization. The evidence concerning patients with concomitant atrial fibrillation appears to be insufficient, however, recent guidelines propose the use of novel oral anticoagulants. Conclusion: For the time being, novel oral anticoagulants in combination with aspirin may provide an alternative treatment in PAD, however, it is deemed necessary to identify patient subgroups who will benefit the most.

scholarly journals Checklists for the use of novel oral anticoagulants by the front-line clinician

2015 ◽  
Vol 148 (5) ◽  
pp. 241-245 ◽  
Author(s):  
Tammy J. Bungard ◽  
Jennifer Bolt ◽  
Peter Thomson ◽  
William Semchuk ◽  
Jennifer Lowerison
Keyword(s):  
Oral Anticoagulants ◽  
Novel Oral Anticoagulants ◽  
Front Line

Novel oral anticoagulants: beyond the myth

2016 ◽  
Vol 33 (1) ◽  
pp. 125-127
Author(s):  
C. Setacci ◽  
M.P. Borrelli ◽  
M. Mele ◽  
G.F. Fadda
Keyword(s):  
Oral Anticoagulants ◽  
Novel Oral Anticoagulants

scholarly journals Protein S deficiency and novel oral anticoagulants: An intriguing case

2014 ◽  
Vol 134 (1) ◽  
pp. 1-2 ◽  
Author(s):  
Dolors Tàssies ◽  
Pablo García de Frutos
Keyword(s):  
Oral Anticoagulants ◽  
Protein S ◽  
Novel Oral Anticoagulants ◽  
Protein S Deficiency ◽  
S Deficiency

scholarly journals Twice- or Once-Daily Dosing of Novel Oral Anticoagulants for Stroke Prevention: A Fixed-Effects Meta-Analysis with Predefined Heterogeneity Quality Criteria

PLoS ONE ◽  
2014 ◽  
Vol 9 (6) ◽  
pp. e99276 ◽  
Author(s):  
Andreas Clemens ◽  
Herbert Noack ◽  
Martina Brueckmann ◽  
Gregory Y. H. Lip
Keyword(s):  
Stroke Prevention ◽  
Fixed Effects ◽  
Meta Analysis ◽  
Oral Anticoagulants ◽  
Quality Criteria ◽  
Novel Oral Anticoagulants ◽  
Once Daily
Sign in / Sign up

Export Citation Format

Share Document